Healthcare
Tenax Therapeutics, Inc.(TENX)
Live Price
Offline$11.93
+0.51% today
1Y Change
+105.01%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $220.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -16.5%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tenax Therapeutics, Inc. (TENX) is a Healthcare stock with a market cap of $220.00M and listed on NASDAQ. The stock last traded around $11.93 and up 105.0% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -16.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -16.5%, free cash flow -141.7% with operating margin 0.0% and ROIC -58.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TENX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -16.5%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -0.1% | +0.8% | -9.9% |
2026 Mar 10, 2026 | +69.8% | +0.8% | +4.5% | +3.7% |
2025 Nov 12, 2025 | +69.9% | -4.3% | +4.7% | +40.9% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TENX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TENX Max Drawdown
-42.31%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TENX and SPY.
Company Overview
Tenax Therapeutics, Inc.
NASDAQ Capital Market
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
- Leadership
- Christopher T. Giordano
- IPO Date
- Apr 4, 1994
- Employees
- 4
- Street Address
- ONE Copley Parkway
- Mailing
- Chapel Hill, NC, 27560
- Region
- Chapel Hill, NC, US
- Reporting Currency
- USD
- Investor Line
- 919 855 2100
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 5.2
Growth
- Revenue
- 0.0%
- EPS
- -16.5%
- Free Cash Flow
- -141.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -51.8%
- ROIC
- -58.1%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 14.56
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.